Literature DB >> 34983974

Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan.

Masayuki Sekine1, Takayuki Enomoto2, Masami Arai3, Shiro Yokoyama4, Hiroyuki Nomura5, Koji Nishino2, Takeshi Ikeuchi6, Yoko Kuriyama7, Seigo Nakamura4.   

Abstract

We previously reported that L63X and Q934X are BRCA1 common founder variants in Japan. So far, there have been no reports of a correlation between such BRCA common variants and the risk of BRCA-related cancers. In this analysis, we investigated the correlation between the risk of ovarian cancer (OC) and BRCA recurrent pathogenic variants. We examined the database of the Japanese organization of hereditary breast and ovarian cancer. The database contained 3517 probands who underwent BRCA genetic testing. Among them, 11.1% (392/3517) had germline BRCA1 pathogenic variant, and 8.3% (293/3517) had BRCA2 pathogenic variant. We calculated the OC prevalence, breast cancer (BC) prevalence, and the ratio of OC to BC within second-degree relatives. The ratio of OC to BC in Q934X family members was significantly higher than that in the overall BRCA1 family members (0.80 vs.0.52: p = 0.038), and the ratio in STOP799 was 0.42, which was relatively lower than the overall BRCA1 value. Both Q934X and STOP799 are located in the ovarian cancer cluster region (OCCR), however there seems to be a difference in the risk of OC. R2318X family members had a significant higher ratio of OC to BC at 0.32 than the overall BRCA2 value of 0.13 (p = 0.012). R2318X is known to be located in the OCCR. This is the first report to investigate the correlation between BRCA recurrent variants and the risk of OC in Japan. The family members of probands with Q934X or R2318X have a higher risk of OC than that with other BRCA variants.
© 2021. The Author(s), under exclusive licence to The Japan Society of Human Genetics.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34983974     DOI: 10.1038/s10038-021-01002-z

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  3 in total

1.  Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Authors:  Jaya M Satagopan; Jeff Boyd; Noah D Kauff; Mark Robson; Lauren Scheuer; Steven Narod; Kenneth Offit
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

2.  Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.

Authors:  M Sekine; H Nagata; S Tsuji; Y Hirai; S Fujimoto; M Hatae; I Kobayashi; T Fujii; I Nagata; K Ushijima; K Obata; M Suzuki; M Yoshinaga; N Umesaki; S Satoh; T Enomoto; S Motoyama; K Tanaka
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

3.  Risk factors for epithelial ovarian cancer in Japan - results from the Japan Public Health Center-based Prospective Study cohort.

Authors:  Elisabete Weiderpass; Sven Sandin; Manami Inoue; Taichi Shimazu; Motoki Iwasaki; Shizuka Sasazuki; Norie Sawada; Taiki Yamaji; Shoichiro Tsugane
Journal:  Int J Oncol       Date:  2011-09-08       Impact factor: 5.650

  3 in total
  1 in total

1.  Prevalence of Pathogenic Germline BRCA1/2 Variants and Their Association with Clinical Characteristics in Patients with Epithelial Ovarian Cancer in a Rural Area of Japan.

Authors:  Akiko Abe; Issei Imoto; Shoichiro Tange; Masato Nishimura; Takeshi Iwasa
Journal:  Genes (Basel)       Date:  2022-06-18       Impact factor: 4.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.